# ClinicalTrials.gov record NCT05048901

> PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct05048901-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05048901-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05048901-lanreotide-v1.json
- Content SHA-256: `284198ac719ebbc50f3d51e693fb301aa6194359bfc2ab3e0d8dd808ac23c497`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05048901 ([`ctg-observation-nct05048901-2026-04-09-469add9afb3b`](#source-ctg-observation-nct05048901-2026-04-09-469add9afb3b))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct05048901-2026-04-09-469add9afb3b`](#source-ctg-observation-nct05048901-2026-04-09-469add9afb3b))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05048901 at 2026-07-30T16:20:49.324Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct05048901-2026-04-09-469add9afb3b`](#source-ctg-observation-nct05048901-2026-04-09-469add9afb3b))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05048901-2026-04-09-469add9afb3b`](#source-ctg-observation-nct05048901-2026-04-09-469add9afb3b))

## Sources

<a id="source-ctg-observation-nct05048901-2026-04-09-469add9afb3b"></a>
- **ClinicalTrials.gov record NCT05048901 · retained source version 2026-04-09:469add9afb3b7afbe257162ff7d0c7b3beea435c4a13f4e8edd86bf6b32e000e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05048901) (`ctg-observation-nct05048901-2026-04-09-469add9afb3b`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05048901." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05048901-lanreotide-v1.json SHA-256: 284198ac719ebbc50f3d51e693fb301aa6194359bfc2ab3e0d8dd808ac23c497.